Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359513 | 0.83 | NAMPT (0.46) | — | |
| SCHEMBL1419617 | 0.83 | MAPK1 (0.54) | SMN1; SMN2HPGDALDH1A1CYP3A4MAPK1 | |
| SCHEMBL2540830 | 0.83 | HPGD (0.55) | SMN1; SMN2HPGDALDH1A1MAPK1MAPT | |
| SCHEMBL1419259 | 0.82 | NPC1 (0.42) | SMN1; SMN2HPGDALDH1A1MAPTRAB9A | |
| SCHEMBL50031 | 0.81 | HSD17B10 (0.57) | SMN1; SMN2HPGDALDH1A1CYP3A4MAPT | |
| SCHEMBL2533532 | 0.80 | HPGD (0.57) | SMN1; SMN2HPGDALDH1A1MAPK1MAPT | |
| SCHEMBL1451293 | 0.80 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1FAAHMAPTGAA | |
| SCHEMBL1419452 | 0.80 | HPGD (0.58) | SMN1; SMN2HPGDALDH1A1MAPK1MAPT | |
| SCHEMBL7016574 | 0.79 | ALDH1A1 (0.53) | SMN1; SMN2HPGDALDH1A1MAPK1MAPT | |
| SCHEMBL962241 | 0.79 | NPSR1 (0.45) | SMN1; SMN2HPGDCYP3A4LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| CN-103097340-A | Therapeutically active compositions and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2013-05-08 | — | — | CN | claimed |
| WO-2012009678-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-6967197-B2 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-22 | — | — | US | claimed |
| CN-1188404-C | Cyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | claimed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1425010-A | Cyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-06-18 | — | — | CN | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | claimed |
| EP-0496608-B1 | Substituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same | ISHIHARA SANGYO KAISHA (JP) | 1995-09-20 | — | — | EP | claimed |
| CN-1077453-A | Substituted pyridinesulfonamide compound or its salt prepare its method and the weedicide that contains it | ISHIHARA SANGYO KAISHA (JP) | 1993-10-20 | — | — | CN | claimed |
| EP-0562731-A1 | Substituted pyridinesulfonamide compounds or their salts, process for preparing the same, and herbicides containing the same | ISHIHARA SANGYO KAISHA, Ltd. (JP) | 1993-09-29 | — | — | EP | claimed |
| EP-0496608-A1 | Substituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same | ISHIHARA SANGYO KAISHA, Ltd. (JP) | 1992-07-29 | — | — | EP | claimed |
| JP-59088457-A | — | — | None | — | — | JP | disclosed |
| WO-2024079287-A1 | COMB POLYMERS | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2024-04-18 | — | — | WO | disclosed |
| US-3992188-A | Herbicidal mixtures of pyridazones and phenylsulfonyl methanesulfone O-alkylbenzene | BASF AKTIENGESELLSCHAFT (DT) | 1976-11-16 | — | — | US | disclosed |
| US-3933460-A | Herbicidal mixture of a benzofuranyl methanesulfonate and a substituted pyridazone | BASF AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | SMN1; SMN2 166/4885HPGD 745/4885ALDH1A1 597/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | SMN1; SMN2 3844/4885HPGD 107/4885ALDH1A1 543/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | SMN1; SMN2 166/4885HPGD 745/4885ALDH1A1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.